Business Context and Reporting Period
This Form 8-K Current Report was filed by OvaScience, Inc. (noted as Tempest Therapeutics, Inc. in request metadata) on December 28, 2012. The filing reports significant changes to the Company's executive leadership and officer appointments effective January 21, 2013.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements.
Material Changes
- Appointment of Chief Operating Officer: Alison Lawton was elected to the office of Chief Operating Officer, effective January 21, 2013. She brings 21 years of experience from Genzyme (Sanofi) and currently serves as a director for Cubist Pharmaceuticals and Verastem, Inc.
- Reassignment of Chief Commercial Officer: Christopher Bleck, the current Chief Operating Officer, was elected to the office of Chief Commercial Officer, effective January 21, 2013.
- Departure of Treasurer: Michael Flanagan ceased to serve as Treasurer, principal financial officer, and principal accounting officer as of December 28, 2012.
- Appointment of Financial Officers: Christopher Bleck was appointed to fill the roles of Treasurer, principal financial officer, and principal accounting officer.
Compensatory Arrangements and Outlook
A Letter Agreement dated December 30, 2012, outlines the compensation for Alison Lawton:
- Base Salary: $350,000 per year.
- Bonus: Eligible for an annual discretionary bonus.
- Equity: Subject to Board approval, options to purchase 368,892 shares of common stock at fair market value on the grant date.
- Benefits: Standard Company benefits, vacation time, and specific termination benefits for "without cause" or "good reason" scenarios.
The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard employment terms.
Investor Verification Checklist
- Verify the exact start date of Alison Lawton's employment (expected January 21, 2013).
- Confirm the Board's final approval of the 368,892 stock options granted to Ms. Lawton.
- Review the transition plan for financial reporting responsibilities following Michael Flanagan's departure.
- Check subsequent filings for the formal employment agreement details beyond the Letter Agreement.